SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023 First oral presentation on SPVN20…
Our Company
Moving beyond single gene correction therapies to deliver new treatments.
We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
Genomic Medicines
Our goal is to harness the potential of gene therapy and genome editing to bring cutting-edge innovation into ocular disease drug discovery and development.
Pipeline
At the heart of this is a pipeline of mutation independent treatments for Inherited Retinal Diseases (IRD) such as Retinitis Pigmentosa (RP), the leading inherited cause of blindness which affects 2 million people worldwide.
Retinitis Pigmentosa
A group of IRDs which are a leading cause of blindness globally. Current monogenic treatment approaches are not applicable to all patients. With our approach we believe that we can bring meaningful differences to many of them.
SPVN06
SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).
Learn More
Combining 20+ years of world-leading ophthalmic research with a world class team of experts from across the international drug development spectrum. SparingVision has an unparalleled understanding of retinal disease and bringing novel treatments to patients.
Investors
Public Funding
